Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rang in aandelen #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Aandeelprijs
$0.01292666
Laatst gesynchroniseerd: 2025-04-08
Marktkapitalisatie
$157.54K
Verandering (1 dag)
6.84%
Verandering (1 jaar)
0.00%
Land
GB
Handel Synairgen plc (SNG)

Categorie

Koersgeschiedenis voor Synairgen plc (SNG)
Hoogste slotkoers: $0.01 op 2025-04-01

Laagste slotkoers: $2.04 op 2004-10-01
Koersgeschiedenis van Synairgen plc van 2004 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2025 -66.26%
2024 -44.21%
2023 -52.93%
2022 -92.61%
2021 77.16%
2020 1,567.16%
2019 -48.13%
2018 14.84%
2017 -14.89%
2016 -49.84%
2015 -35.02%
2014 -37.63%
2013 15.10%
2012 50.92%
2011 14.84%
2010 -28.85%
2009 88.33%
2008 -77.12%
2007 -24.86%
2006 -99.32%
2005 209.00%
2004 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$517.18 30.63%
US
$857.76 32.66%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE